BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy

Korábbi kezelés

• Prior topoisomerase inhibitor-based ADC therapy.
• Other prior or concurrent malignancies except for certain localized cancers or low-grade prostate cancer (if approved by sponsor), or other malignancy treated with curative intent with a disease-free interval of at least 3 years.
• Prior history of clinically significant bleeding, or perforation of the gastrointestinal tract within 6 months of randomization.
• History of noninfectious interstitial lung disease (ILD)/pneumonitis that required treatment with steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
• Advanced/clinically significant lung disease (eg, poorly controlled chronic obstructive pulmonary disease or asthma, restrictive lung disease, or pulmonary hypertension) within 6 months prior to randomization.

Más betegség

• Bladder cancers with small cell histology.
• Active autoimmune diseases and inflammatory diseases.
• Known human immunodeficiency virus infection.
• Active hepatitis B virus (HBV) infection.
• Active hepatitis C virus (HCV) infection.
• Active or latent tuberculosis.

Egyéb

• Primary tumors in the central nervous system (CNS), active or untreated CNS metastases, or carcinomatous meningitis.
• Other protocol-specified inclusion/ exclusion criteria apply

• Histologically or cytologically documented metastatic or surgically unresectable transitional cell carcinoma (TCC) of the urothelium involving the renal pelvis, ureter, bladder, or urethra. Minor histologic variants (ie, <50% overall) are acceptable, provided that TCC is the dominant histology.
• Disease progression or recurrence during or following anti-PD-(L)1-based therapy.
• Fresh biopsy or archival tumor samples.
• Documented HER2 expression by central laboratory testing.
• Eligible to receive carboplatin or cisplatin in combination with gemcitabine.
• At least 1 measurable lesion based on RECIST v1.1.
• An Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.
• Adequate organ function.
• Adequate coagulation parameters.